Consistency of atypical antipsychotic superiority to placebo in recent clinical trials (Q31864376)

4 July 2017

0 references

Consistency of atypical antipsychotic superiority to placebo in recent clinical trials (English)

1 reference

4 July 2017

1 reference

S W Woods

1

1 reference

4 July 2017

M Stolar

series ordinal

2

1 reference

4 July 2017

M J Sernyak

series ordinal

3

1 reference

4 July 2017

D S Charney

series ordinal

4

1 reference

4 July 2017

language of work or name

English

0 references

publication date

1 January 2001

1 reference

4 July 2017

Biological Psychiatry

1 reference

4 July 2017

49

1 reference

4 July 2017

1

1 reference

4 July 2017

64-70

1 reference

The use of placebos in clinical trials for acute schizophrenia.

4 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Olanzapine versus placebo: results of a double-blind, fixed-dose olanzapine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

ICI 204,636, an atypical antipsychotic: efficacy and safety in a multicenter, placebo-controlled trial in patients with schizophrenia. U.S. SEROQUEL Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

The rationale and ethics of medication-free research in schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

ICI 204,636, a novel, atypical antipsychotic: early indication of safety and efficacy in patients with chronic and subchronic schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Another view of active-controlled trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Trials to assess equivalence: the importance of rigorous methods

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Ziprasidone 40 and 120 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 4-week placebo-controlled trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Hazards of inference: the active control investigation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Risperidone in the treatment of schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Inherent difficulties with active control equivalence studies.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Placebo-controlled trials: when are they needed?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Problems in interpreting active control equivalence trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

When are clinical trials of a given agent vs. placebo no longer appropriate or feasible?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

When placebo controlled trials are essential and equivalence trials are inadequate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

A randomized, controlled, dose-ranging trial of sertindole in patients with schizophrenia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Placebo-controlled trials in schizophrenia: are they ethical? Are they necessary?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Controlled, dose-response study of sertindole and haloperidol in the treatment of schizophrenia. Sertindole Study Group

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

Placebo-controlled studies in schizophrenia--ethical and scientific perspectives: an overview of conference proceedings.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS0006-3223%2800%2900973-2

10.1016/S0006-3223(00)00973-2

7 January 2021

Identifiers

DOI

1 reference

release_akwwwq2h6fakdi3i276sfvqyce

4 July 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/akwwwq2h6fakdi3i276sfvqyce

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference